Rapid test to identity myeloma kidney by measurement of serum free light chains

Monoclonal κ and λ immunoglobulin free light chains (FLC) in blood and urine are important biomarkers to determine if acute kidney injury (AKI) may be attributable to a plasma cell dyscrasia. Laboratory FLC tests offer the only means of detecting FLC and commonly have a slow turnaround time that delays early diagnosis of myeloma kidney and thus increases risk of kidney damage. We have developed a point-of-care (POC) lateral flow test that can rapidly measure FLC levels in blood or urine in 10 minutes. The POC test simultaneously quantitates κ and λ FLC levels using highly specific anti-κ and anti-λ FLC monoclonal antibodies (abstract also submitted). POC capture antibodies displayed no cross-reactivity to bound LC on whole immunoglobulin, the alternate LC type, or other human proteins, and had excellent sensitivity